Thrombosis Drugs Market Size

Thrombosis Drugs Market Size

Thrombosis Drugs Market size was valued at around USD 31.2 billion in 2023 and is estimated to grow at a CAGR of 8.2% between 2024 and 2032. This robust market growth can be attributed to various factors, including ongoing advancements in drug development, an increase in the prevalence of thrombotic disorders, growing geriatric population, rising number of surgical procedures, and the continual growth of healthcare expenditure, among other contributing factors.

To get key market trends

  Download Free Sample

Furthermore, thrombotic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction, are becoming more prevalent worldwide. Factors such as sedentary lifestyles, obesity, and the increasing incidence of chronic conditions like diabetes and cardiovascular diseases are contributing to the growing burden of thrombotic disorders. Consequently, there is a rising demand for thrombosis medications for both treatment and prevention.
 

For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., approximately 900,000 individuals were affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) annually. The aging population worldwide is more susceptible to thrombotic disorders due to age-related changes in the vascular system, increased comorbidities, and reduced mobility. As the elderly population continues to grow, there is a corresponding increase in the prevalence of thrombotic disorders, driving the demand for thrombosis drugs.
 

Thrombosis drugs are medications used for the prevention and treatment of thrombotic disorders, which involve the formation of blood clots within blood vessels. These drugs act through various mechanisms to inhibit the coagulation cascade, prevent platelet aggregation, and/or dissolve existing blood clots.